Initially funded by a New Investigator award in Diabetes Mellitus and then the current RO1 my laboratory has developed and characterized a series of monoclonal anti-islet antibodies, discovered that islets express complex glycolipids (ganglioside receptors for monoclonals, A2B5, 3G5, and tetanus toxin), provided evidence that a major subset of patients anti-islet autoantibodies react with similar glycolipids, discovered a series of islet glycoprotein antigens (p120 """"""""calcium modulator"""""""", monoclonals 4F2 and LC7/2; p67, monoclonal HISL-19; p100, monoclonals HISL-5, 9 and 14; p24 monoclonal AID2), assessed physiologic effects of monoclonal antibody binding to the surface of neurendocrine cells, developed a clinical double immunoflourescent anti-islet antibody assay utilizing rhodaminated monoclonal BISL-32, described the T lymphopenia of the BB rat and its relation to diabetes in breeding studies, described Ia positive T cells associated with Type I diabetes, discovered the 3G5 T cell subset which increases linearly with age in man, and characterized immunologic and metabolic assays which on a research basis allow us to predict the development and approximate time of onset of Type I diabetes. A balance of immune destruction and beta cell regeneration may determine the rate at which Type I diabetes develops in the BB rat, NOD mouse and man. With the above background information, reagents, and prospective clinical studies, major goals of the current project include; 1) biochemical characterization of the islet complex glycolipids which are receptors for monoclonal antibodies A2B5, 3G5 and patients autoantibodies. 2) development of quantitative assays for autoantibodies reacting with these glycolipids, and 3) pilot studies of cell mediated immune responses to purified glycolipids and linkage in the NOD mouse of glycolipid polymorphisms to diabetogenic genes. In addition we propose to utilize our current series of monoclonal anti-islet antibodies and new monoclonals specifically produced to regenerating rat islets to study islet cell growth. In our partial pancreatectomy model of islet regeneration we propose to study; 1) monoclonal antibody defined islet differentiation antigens, 2) islet """"""""microenvironment"""""""" antigens (e.g., Factor VIII, MHC class I and class II antigens), 3) islet """"""""activation"""""""" antigens, and 4) the ability of specific monoclonal antibodies to stimulate islet cell growth.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK032083-08
Application #
3230549
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1982-07-15
Project End
1992-06-30
Budget Start
1989-07-01
Budget End
1990-06-30
Support Year
8
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Joslin Diabetes Center
Department
Type
DUNS #
071723084
City
Boston
State
MA
Country
United States
Zip Code
02215
Michels, Aaron W; Gottlieb, Peter A (2018) Learning From Past Failures of Oral Insulin Trials. Diabetes 67:1211-1215
Steck, Andrea K; Dong, Fran; Frohnert, Brigitte I et al. (2018) Predicting progression to diabetes in islet autoantibody positive children. J Autoimmun 90:59-63
Liu, Chih-Wei; Bramer, Lisa; Webb-Robertson, Bobbie-Jo et al. (2018) Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression. J Proteomics 172:100-110
Wang, Yang; Sosinowski, Tomasz; Novikov, Andrey et al. (2018) C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A 115:162-167
Frohnert, Brigitte I; Laimighofer, Michael; Krumsiek, Jan et al. (2018) Prediction of type 1 diabetes using a genetic risk model in the Diabetes Autoimmunity Study in the Young. Pediatr Diabetes 19:277-283
Akturk, Halis Kaan; Alkanani, Aimon; Zhao, Zhiyuan et al. (2018) PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab 103:3589-3592
Ostrov, David A; Alkanani, Aimon; McDaniel, Kristen A et al. (2018) Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest 128:1888-1902
Burrack, Adam L; Landry, Laurie G; Siebert, Janet et al. (2018) Simultaneous Recognition of Allogeneic MHC and Cognate Autoantigen by Autoreactive T Cells in Transplant Rejection. J Immunol 200:1504-1512
Waugh, Kathleen; Snell-Bergeon, Janet; Michels, Aaron et al. (2017) Increased inflammation is associated with islet autoimmunity and type 1 diabetes in the Diabetes Autoimmunity Study in the Young (DAISY). PLoS One 12:e0174840
Michels, Aaron W; Landry, Laurie G; McDaniel, Kristen A et al. (2017) Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes 66:722-734

Showing the most recent 10 out of 234 publications